<DOC>
	<DOC>NCT00353756</DOC>
	<brief_summary>The purpose of this study is to determine whether C326, a new inhibitor of IL-6, is safe in patients with Crohn's disease.</brief_summary>
	<brief_title>Phase 1 Study of Safety and Biological Effects of C326, an Inhibitor of IL-6, in Crohnâ€™s Disease</brief_title>
	<detailed_description>Determination of safety is the most important goal of this first study with C326. Other goals of the study are to examine: - pharmacokinetics (change in serum concentrations over time), - biological activity (change in blood markers relecting activity of Crohn's Disease), - effects on symptoms of Crohn's disease. Participants may receive either a single or several intravenous infusions of C326 or matching placebo.</detailed_description>
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Adults 18 65 Stable, moderately active Crohn's Disease Otherwise in generally good health Variety of concurrent medical conditions Various concomitant medications</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>